Health News from Medical News Today: Celgene And Acceleron Initiate Phase 2/3 Study Of ACE-011 (Sotatercept) To Treat Chemotherapy-Induced Anemia In Patients With Lung Cancer

Health News from Medical News Today Latest Health News and Medical News posted throughout the day, every day. Celgene And Acceleron Initiate Phase 2/3 Study Of ACE-011 (Sotatercept) To Treat Chemotherapy-Induced Anemia In Patients With Lung Cancer 3 Jun 2011, 5:00 pm Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation (NASDAQ: CELG) today announced the initiation of the first part of a Phase 2/3 clinical study of ACE-011 (sotatercept) for the treatment of chemotherapy-induced anemia (CIA) in patients with metastatic non-small cell lung cancer (NSCLC). Celgene Corporation will make a $7 million milestone payment to Acceleron in accordance with the terms of the collaboration agreement between the two companies... You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed.